Dr Lal PathLabs Q4 net profit falls 8% to Rs 57 crore
Revenue from operations rose to Rs 491 crore for the fourth quarter as compared with Rs 485 crore in the year-ago period, Dr Lal PathLabs said in a regulatory filing.
Dr Lal PathLabs on Thursday said its consolidated profit after tax declined 8 per cent to Rs 57 crore for the fourth quarter ended March 31, 2023.
The company had reported a net profit of Rs 62 crore in the January-March quarter a year ago.
Revenue from operations rose to Rs 491 crore for the fourth quarter as compared with Rs 485 crore in the year-ago period, Dr Lal PathLabs said in a regulatory filing.
For the year ended March 31, 2023, the company reported a consolidated net profit of Rs 241 crore as against Rs 350 crore in FY22.
The company said its board has recommended a final dividend of Rs 6 per share (60 per cent) on a face value of Rs 10 per share for the year ended March 31, 2023.
Shares of the company ended 2.21 per cent down at Rs 1,906.80 apiece on the BSE.
Catch the latest stock market updates here. For more news on sports, politics follow Zee Business
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
IRCTC Dividend 2024: Railway PSU announces 200% interim dividend - Check record date and other details
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
05:51 PM IST